HK1210598A1 - Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation -- - Google Patents

Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation --

Info

Publication number
HK1210598A1
HK1210598A1 HK15111382.6A HK15111382A HK1210598A1 HK 1210598 A1 HK1210598 A1 HK 1210598A1 HK 15111382 A HK15111382 A HK 15111382A HK 1210598 A1 HK1210598 A1 HK 1210598A1
Authority
HK
Hong Kong
Prior art keywords
tri
inhibitors
protein aggregation
heteroaryl derivatives
heteroaryl
Prior art date
Application number
HK15111382.6A
Other languages
English (en)
Chinese (zh)
Inventor
Wolfgang Wrasidlo
Original Assignee
Neuropore Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropore Therapies Inc filed Critical Neuropore Therapies Inc
Publication of HK1210598A1 publication Critical patent/HK1210598A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15111382.6A 2012-07-16 2015-11-18 Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation -- HK1210598A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672239P 2012-07-16 2012-07-16
PCT/US2013/050719 WO2014014937A1 (en) 2012-07-16 2013-07-16 Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation

Publications (1)

Publication Number Publication Date
HK1210598A1 true HK1210598A1 (en) 2016-04-29

Family

ID=49949212

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111382.6A HK1210598A1 (en) 2012-07-16 2015-11-18 Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation --

Country Status (15)

Country Link
US (1) US9284309B2 (he)
EP (1) EP2872143B1 (he)
JP (1) JP2015522617A (he)
KR (1) KR20150031481A (he)
CN (1) CN104703604A (he)
AU (1) AU2013290361A1 (he)
BR (1) BR112015001096A2 (he)
CA (1) CA2877983A1 (he)
ES (1) ES2661394T3 (he)
HK (1) HK1210598A1 (he)
IL (1) IL236712A0 (he)
IN (1) IN2015DN01171A (he)
MX (1) MX2015000618A (he)
RU (1) RU2015104962A (he)
WO (1) WO2014014937A1 (he)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3348556T3 (da) 2014-01-29 2020-08-03 UCB Biopharma SRL Heteroarylamider som hæmmere af proteinaggregering
ES2885049T3 (es) 2015-07-29 2021-12-13 UCB Biopharma SRL Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
RU2019126170A (ru) 2017-01-26 2021-02-26 Юсб Байофарма Спрл Бисгетероарильные производные в качестве модуляторов агрегации белков
ES2918048T3 (es) * 2017-01-26 2022-07-13 UCB Biopharma SRL Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas
CN110167937B (zh) 2017-01-26 2022-03-29 Ucb生物制药私人有限公司 作为蛋白质聚集调节剂的二环双-杂芳基衍生物
WO2018158160A1 (en) 2017-02-28 2018-09-07 Universitat Autonoma De Barcelona (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies
WO2019025424A1 (en) 2017-08-04 2019-02-07 Universitat Autonoma De Barcelona COMPOUNDS FOR TREATING SYNUCLEINOPATHIES
WO2019161917A1 (en) 2018-02-23 2019-08-29 Universitat Autonoma De Barcelona 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies
CN113683598B (zh) * 2020-05-18 2022-10-14 成都先导药物开发股份有限公司 一种免疫调节剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4739632B2 (ja) 2000-02-05 2011-08-03 バーテックス ファーマシューティカルズ インコーポレイテッド Erkのインヒビターとして有用なピラゾール組成物
DE60122176T2 (de) 2000-09-15 2007-07-05 Vertex Pharmaceuticals Inc., Cambridge Isoxazole und ihre verwendung als erk-inhibitoren
CA2494942A1 (en) * 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
MA33304B1 (fr) 2009-04-30 2012-05-02 Glaxo Group Ltd Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
MX335989B (es) * 2009-12-16 2016-01-07 Neuropore Therapies Inc Compuesto adecuado para el tratamiento de sinucleopatias.
US9198891B2 (en) * 2010-05-21 2015-12-01 New York University Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase

Also Published As

Publication number Publication date
JP2015522617A (ja) 2015-08-06
KR20150031481A (ko) 2015-03-24
RU2015104962A (ru) 2016-09-10
WO2014014937A1 (en) 2014-01-23
BR112015001096A2 (pt) 2017-06-27
US20150183776A1 (en) 2015-07-02
EP2872143A4 (en) 2015-12-02
ES2661394T3 (es) 2018-03-28
IL236712A0 (he) 2015-02-26
EP2872143A1 (en) 2015-05-20
CN104703604A (zh) 2015-06-10
AU2013290361A1 (en) 2015-02-05
MX2015000618A (es) 2015-04-10
CA2877983A1 (en) 2014-01-23
IN2015DN01171A (he) 2015-06-26
US9284309B2 (en) 2016-03-15
EP2872143B1 (en) 2017-12-13

Similar Documents

Publication Publication Date Title
ZA201600648B (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
HK1215578A1 (zh) 作為蛋白激酶抑制劑的氮雜吲哚衍生物
SI2920149T1 (sl) Spojine 3-aminocikloalkila kot zaviralci receptorja ROR-gama-t in uporaba teh spojin
HK1211027A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors pi3k
HK1210598A1 (en) Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation --
PL2880035T3 (pl) Nowe związki pirolopirymidynowe jako inhibitory kinaz białkowych
HK1203949A1 (en) Inhibitors of iap iap
EP2838531A4 (en) INDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
HK1210036A1 (en) Aminoisoquinoline derivatives as protein kinase inhibitors
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
EP3560952C0 (en) VARIANT OF BPIFB4 PROTEIN
EP2879681A4 (en) INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6